Celgene Corp. (CELG) Gets Verbal Confirmation of Early HSR Act Termination in Abraxis (ABII) Acquisition
Celgene Corporation (Nasdaq: CELG) today announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regard to Celgene’s pending acquisition of Abraxis Bioscience, Inc. (Nasdaq: ABII).
Celgene anticipates that the transaction will be completed in the third or fourth quarter of 2010.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Celgene anticipates that the transaction will be completed in the third or fourth quarter of 2010.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Bazaarvoice (BV) Agrees to Buy PowerReviews; Offers Prelim. Q1 Results, Guides Q2, FY13
- China Investment may nab $2B stake in Alibaba - Reuters
- Sony (SNE) Said to Pay for 3-D Glasses for 'Men In Black 3' -Bloomberg (RLD)
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
